Inactive Instrument

Amarin Corporation plc (ADR) Xetra

Equities

EH3A

US0231112063

Biotechnology & Medical Research

End-of-day quote Xetra Other stock markets
- ^EUR	-

Jul. 12	European Equities Traded in the US as American Depositary Receipts Climb Higher in Friday Trading	MT
Jul. 11	European Equities Traded in the US as American Depositary Receipts Rise Slightly in Thursday Trading	MT

Amarin Corporation plc (ADR) : Amarin Announces Market Introduction of Vascepa(R) (icosapent ethyl) Capsules for the Treatment of Very High Triglycerides (VHTG)

January 24, 2013 at 08:25 am EST

MarketScreener.com By

-First and Only FDA Approved Pure-EPA Omega-3 Prescription Therapy Now Available-

-Vascepa Reduces VHTG Without Raising LDL Cholesterol-

BEDMINSTER, N.J., and DUBLIN, Ireland, Jan. 24, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that Vascepa® (icosapent ethyl) capsules, a therapy for patients in the United States to treat severe (

Latest news about Amarin Corporation plc (ADR)

European Equities Traded in the US as American Depositary Receipts Climb Higher in Friday Trading	Jul. 12	MT
European Equities Traded in the US as American Depositary Receipts Rise Slightly in Thursday Trading	Jul. 11	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading	Jul. 10	MT
European Equities Traded in the US as American Depositary Receipts Flat in Monday Trading	Jul. 08	MT
Sector Update: Health Care Stocks Edge Higher Premarket Monday	Jul. 08	MT
Amarin Commercial Partner in China Receives Regulatory Approval for Heart Drug Vascepa	Jul. 08	MT
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading	Jul. 05	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	Jun. 26	MT
European Equities Traded in the US as American Depositary Receipts Nudge Higher Tuesday Trading	Jun. 25	MT
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading	Jun. 24	MT
European Equities Traded in the US as American Depositary Receipts Rise Sharply in Wednesday Trading	Jun. 12	MT
European Equities Traded in the US as American Depositary Receipts Trend Sharply Lower in Tuesday Trading	Jun. 11	MT
European Equities Traded in the US as American Depositary Receipts Lower in Monday Trading	Jun. 10	MT
Tech Firms Lead European Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading	Jun. 06	MT
European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading	Jun. 05	MT
Sector Update: Health Care Stocks Rise Late Afternoon	Jun. 04	MT
Sector Update: Health Care Stocks Rise Tuesday Afternoon	Jun. 04	MT
Sector Update: Health Care	Jun. 04	MT
Amarin Shares Fall After CEO Resignation	Jun. 04	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading	Jun. 04	MT
Amarin Names Aaron Berg as Chief Executive Officer	Jun. 04	MT
Amarin Corporation plc Announces CEO Changes	Jun. 04	CI
Amarin Corporation plc Announces Executive Changes	Jun. 04	CI
European Equities Traded in the US as American Depositary Receipts Open Week Lower in Tuesday Trading	May. 28	MT
Amarin Says Greece Approves Vazkepa for National Reimbursement; Signs Commercialization Agreement With Vianex	May. 28	MT

Chart Amarin Corporation plc (ADR)

Duration

Period

More charts

Company Profile

Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.

Sector

Biotechnology & Medical Research

Calendar

2024-07-30 - Q2 2024 Earnings Release (Projected)

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+20.12%	126B
REGENERON PHARMACEUTICALS, INC.	+25.25%	119B
ARGENX SE	+25.56%	27.95B
BIONTECH SE	-19.51%	20.5B
GENMAB A/S	-14.36%	17.12B
BEIGENE, LTD.	-15.63%	16.1B
WUXI APPTEC CO., LTD.	-46.67%	14.97B
NEUROCRINE BIOSCIENCES, INC.	+11.89%	14.84B
SAREPTA THERAPEUTICS, INC.	+57.74%	14.38B

Bio Therapeutic Drugs